false
0000001800
Common Shares, Without Par Value
ABT
0000001800
2025-11-18
2025-11-18
0000001800
us-gaap:CommonStockMember
exch:XCHI
2025-11-18
2025-11-18
0000001800
us-gaap:CommonStockMember
exch:XNYS
2025-11-18
2025-11-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
| Common Shares, Without Par Value |
|
ABT |
|
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
November 18, 2025
Date of Report (Date of earliest event reported)
ABBOTT LABORATORIES
(Exact name of registrant as specified in
charter)
| Illinois |
|
1-2189 |
|
36-0698440 |
| (State or other Jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
| of Incorporation) |
|
|
|
Identification No.) |
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
(Address of principal executive offices)(Zip
Code)
Registrant’s telephone number, including
area code: (224) 667-6100
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered Pursuant to Section 12(b) of
the Act:
| Title of Each Class |
Trading
Symbol(s) |
Name of Each Exchange
on Which Registered |
| Common
Shares, Without Par Value |
ABT |
New
York Stock Exchange
NYSE Texas |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 5.04 | Temporary Suspension of Trading Under Registrant’s Employee Benefit Plans |
On November 18, 2025, Abbott Laboratories (“Abbott”) received
a notice from the plan administrator of the Abbott Laboratories Stock Retirement Plan (“U.S. Plan”) and the Abbott Laboratories
Stock Retirement Plan (Puerto Rico) (“P.R. Plan”; collectively, the “Plans”) pursuant to Section 101(i)(2)(E)
of the Employee Retirement Income Security Act of 1974 regarding a blackout period (the “Blackout Period”) under the Plans.
The Blackout Period is required because the Plans are making certain administrative changes, including changing the recordkeeper, changing
the trustee for certain funds of the U.S. Plan, and changing the custodian of certain funds of the P.R. Plan.
During the Blackout Period, Plan participants will be unable to engage
in transactions involving the assets held in their Plan accounts, including changing contribution rates, directing or diversifying investments
(including investments in Abbott common shares), or obtaining a Plan loan, withdrawal, or distribution.
As described more fully in the Notice (as defined below), the Blackout
Period is expected to begin on December 24, 2025 at 12 p.m. CST and expected to end during the week of January 11, 2026. During the Blackout
Period and for two years after the ending date of the Blackout Period, a security holder or other interested person may obtain, without
charge, information regarding the Blackout Period, including the actual beginning and ending dates of the Blackout Period, by submitting
a request to Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, Attn: Divisional Vice President, Compensation and
Benefits; (224) 667-6100.
On November 21, 2025, Abbott sent a notice to its directors and executive
officers (the “Notice”) informing them of the Blackout Period and the restrictions on trading in Abbott common shares that
apply to them during the Blackout Period, pursuant to Section 306 of the Sarbanes-Oxley Act of 2002 and Rule 104 of Regulation BTR. A
copy of the Notice is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference.
| Item 9.01 | Financial Statements and Exhibits |
| 99.1 | Notice provided to directors and executive officers of Abbott Laboratories on November 21, 2025. |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
ABBOTT LABORATORIES |
| |
|
|
| Date: November 21, 2025 |
By: |
/s/ Philip P. Boudreau |
| |
|
Philip P. Boudreau |
| |
|
Executive Vice President, Finance and Chief Financial Officer |
